Drug Profile
Somapacitan - Novo Nordisk
Alternative Names: Albumin-binding somatropin - Novo Nordisk; Growth hormone derivative - Novo Nordisk; Long-acting growth hormone - Novo Nordisk; Long-acting somatropin - Novo Nordisk; NN 8640; NNC-0195-0092; Sogroya; Somatropin derivative - Novo Nordisk; Somatropin long acting - Novo NordiskLatest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Growth hormones; Hormonal replacements; Tetrazoles
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Somatotropin deficiency
Most Recent Events
- 18 Dec 2023 Novo Nordisk completes the phase III trial in Somatotropin deficiency (In children) in China (SC) (NCT04970654)
- 23 Aug 2023 Registered for Somatotropin deficiency (In adolescents, In children) in European Union (SC) (Novo Nordisk presentation, August 2023)
- 23 Aug 2023 Registered for Somatotropin deficiency (In children) in Japan (SC) (Novo Nordisk presentation, August 2023)